Trial Profile
An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms AZURE
- Sponsors Bayer; Bayer HealthCare
- 06 Jan 2024 Primary endpoint has been met. (Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye), as per Results published in the Advances in Therapy
- 06 Jan 2024 Results published in the Advances in Therapy
- 24 Jun 2020 Status changed from active, no longer recruiting to completed.